超越基因型:对APOEe4在阿尔茨海默病中的作用的多组分析
Yaroslav Markov1, Ahana Priyanka2, Leqi Xu3
1Program in Computational Biology and Biomedical Informatics, Yale University, New Haven, CT, USA.
bioRxiv : the preprint server for biology
|November 24, 2025
概括
APOEe4基因变异通过早期的突触和代谢变化,晚期的炎症反应和表观遗传变化增加了阿尔茨海默病的风险. 这些分子变化,而不是一般的多基因风险,推动了携带者疾病的发展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,具有重要的遗传基础.
- APOEe4等位基因是阿尔茨海默氏症最强的遗传风险因素,但其确切的机制尚不清楚.
- 了解APOEe4的分子影响对于开发向疗法至关重要.
研究的目的:
- 研究APOEe4影响阿尔茨海默病风险的蛋白质组,表观遗传和遗传机制.
- 区分APOEe4驱动的病理和大脑中的补偿反应.
- 为了确定潜在的生物标志物和治疗目标,特定于APOEe4载体.
主要方法:
- 来自ROSMAP队列的死后大脑样本 (n=302) 的蛋白质组,DNA甲基化和全基因组测序数据的分析.
- 基于APOEe4载体状态和AD病理学的样本分层.
- 计算多基因风险得分 (PRS) 和应用网络和调解分析.
主要成果:
- 在非痴呆的APOEe4载体中,蛋白质水平降低表明早期的突触和代谢脆弱性.
- 在AD的APOEe4载体中,观察到炎症和蛋白质静止蛋白的增加以及ELAVL4高甲基化.
- 特定蛋白质 (GRIPAP1,GSTK1,VAMP1,CASKIN1,DPP3,SYN3,FGG) 和ELAVL4的高甲基化介导了APOEe4对AD风险的影响.
- 蛋白质和表观遗传标记,而不是PRS,在APOEe4载体中更能预测AD.
结论:
- APOEe4通过早期的突触/代谢缺陷以及后来的炎症/表观遗传变化,使得阿尔茨海默病的风险增加.
- 确定的分子通路是针对APOEe4的特异性,并不能通过一般的多基因风险来解释.
- 这些发现支持基因型定制生物标志物和阿尔茨海默病治疗策略的开发.
更多相关视频
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
34.5K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
